Quick Takeaways
- Robert Nelsen has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $341,164,193.
- Recent insider filing activity is available below.
- Info
- Significant Ownership
- Insider Ownership
Insider Trading & Ownership of Robert Nelsen
- Location
- Chicago, IL
- Summary
- The estimated net worth of Robert Nelsen is at least $341,164,193 dollars as of 05 Aug 2025. Robert Nelsen is the Director of Denali Therapeutics Inc. and owns shares of Denali Therapeutics Inc. (DNLI) stock worth about $178.33M. Robert Nelsen is the Director, 10%+ Owner of Lyell Immunopharma, Inc. and owns shares of Lyell Immunopharma, Inc. (LYEL) stock worth about $83.02M. Robert Nelsen is the Director, 10%+ Owner of Prime Medicine, Inc. and owns shares of Prime Medicine, Inc. (PRME) stock worth about $73.95M. Robert Nelsen is the Director of Vir Biotechnology, Inc. and owns shares of Vir Biotechnology, Inc. (VIR) stock worth about $5.87M.
- Signature
- /s/ Ryan Brown, attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Robert Nelsen and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Denali Therapeutics Inc. ($178,327,354).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Robert Nelsen
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | Director | $178,327,354 | 02 Jun 2021 | ||
| LYEL | Lyell Immunopharma, Inc. | Director, 10%+ Owner | $83,020,992 | 14 Jun 2024 | ||
| PRME | Prime Medicine, Inc. | Director, 10%+ Owner | $73,946,120 | +$9,999,990 | +16% | 01 Aug 2025 |
| VIR | Vir Biotechnology, Inc. | Director | $5,869,727 | 30 May 2024 | ||
| SANA | Sana Biotechnology, Inc. | Director, 10%+ Owner | 05 Jun 2025 |
Insider Transactions Reported by Robert Nelsen:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.